Design and screening of antisense oligonucleotides (ASOs)
This protocol is extracted from research article:
Functional roles of antisense enhancer RNA for promoting prostate cancer progression
Theranostics, Jan 1, 2021; DOI: 10.7150/thno.51931

The ASOs were designed using a full phosphorothioate backbone and a 10-base 2′-deoxynucleoside gap flanked by 2′-O-methyl (cMt)-modified nucleotides. The motif for the ASOs targeting the eRNAs tested was mmm-10-mmm, where m represents cMt modification and -10- represents the 10-base DNA gap. ASOs were synthesized and purified as described previously 40. A large number of ASOs were screened by BGI Genomics Inc. (Shenzhen, China) for high efficient reduction of RNA.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.